Combined Imaging With 18f-Fdg-Pet/Ct And 111in-Labeled Octreotide Spect For Evaluation Of Thymic Epithelial Tumors(447 views) De Luca S, Fonti R, Palmieri G, Federico P, Del Prete G, Pacelli R, Pace L, De Placido S, Salvatore M, Del Vecchio S
Clin Nucl Med (ISSN: 1536-0229, 0363-3976, 0363-9762), 2013; 38(5): 354-358.
Keywords: 111in-Octreotide, 18f-Fdg-Pet Ct, Functional Imaging, Multimodality Imaging, Thymic Epithelial Tumors, Thymic Neuroendocrine Tumors, Fluorodeoxyglucose F 18, Pentetreotide, Pentetreotide In 111, Adult, Article, Cancer Risk, Clinical Evaluation, Computer Assisted Emission Tomography, Controlled Study, Correlational Study, Drug Uptake, Epithelium Tumor, Female, Human, Primary Tumor, Statistical Significance, Thymic Epithelium Tumor, Thymoma, World Health Organization, Middle Aged, Neoplasms, Glandular And Epithelial, Positron-Emission Tomography And Computed Tomography, Retrospective Studies, Roc Curve, Thymus Neoplasms, Emission-Computed, Single-Photon,
Affiliations: *** IBB - CNR ***
Department of Biomorphological and Functional Sciences, University of Naples Federico II, Via Pansini 5 Edificio 10, 80131 Napoli, Italy
Institute of Biostructures and Bioimages, National Research Council, Italy
Department of Endocrinology and Molecular and Clinical Oncology, University of Naples Federico II, Italy
Rare Tumors Excellence Center, University Hospital Federico II, Naples, Italy
Department of Medicine and Surgery, University of Salerno, Salerno, Italy
References: Not available.
Combined Imaging With 18f-Fdg-Pet/Ct And 111in-Labeled Octreotide Spect For Evaluation Of Thymic Epithelial Tumors
PURPOSE: This study aimed to test the role of combined imaging with F-FDG-PET/CT and In-octreotide SPECT in characterizing thymic epithelial tumors (TETs). METHODS: We evaluated 20 patients with newly diagnosed TETs who had undergone concomitant F-FDG-PET/CT and In-octreotide SPECT. Thymic epithelial tumors were classified by World Health Organization (WHO) as low-risk thymomas (5), high-risk thymomas (4), and thymic carcinomas (11, among which 6 neuroendocrine tumors). Patients were staged according to Masaoka system. F-FDG-PET/CT was performed and SUVmax of primary tumors was recorded. In-octreotide SPECT of the thorax was performed, and tumor-to-background ratio was determined on the 24-hour coronal sections. RESULTS: All patients showed increased F-FDG uptake in mediastinal lesions. SUVmax were significantly correlated with WHO classification (r = 0. 66, P < 0. 01) and with Masaoka stage (r = 0. 60, P < 0. 01). SUVmax of low-risk thymomas (mean [SD], 2. 87 [0. 83]) were significantly lower than those of high-risk thymomas (mean [SD], 7. 21 [1. 73], P < 0. 01) and of thymic carcinomas (mean [SD], 9. 39 [5. 80], P < 0. 05), whereas no significant difference was found between high-risk thymomas and thymic carcinomas. SUVmax of all high-risk thymomas and thymic carcinomas was 4. 5 or greater. All primary tumors were detected by In-octreotide SPECT, and tumor-to-background ratios ranged between 1. 67 and 10. 10. No statistically significant correlation was found between tumor-to-background ratios and WHO classification (r = 0. 24, P = 0. 36) and Masaoka stages (r = 0. 31, P = 0. 23). However tumor-to-background ratios of thymic neuroendocrine tumors (mean [SD], 5. 71 [3. 09]) were significantly higher than those of all other TETs with SUVmax of 4. 5 or greater (mean [SD], 2. 41 [0. 56]; P < 0. 05). CONCLUSIONS: F-FDG-PET/CT scan allows to differentiate high-risk epithelial tumors and thymic carcinomas from low-risk thymomas, whereas In-octreotide SPECT may identify neuroendocrine tumors among those showing high F-FDG uptake. 2013 by Lippincott Williams & Wilkins
Combined Imaging With 18f-Fdg-Pet/Ct And 111in-Labeled Octreotide Spect For Evaluation Of Thymic Epithelial Tumors